Wegovy May Protect the Heart Better Than Mounjaro

10 October, 2025  |  Holy Winter - Healthcare Writer

Two leading weight loss drugs, Wegovy and Mounjaro, can help shed pounds; however, recent studies have shown how they may also help to protect your heart.

Here iQ Doctor provides the lowdown on where weight loss meets heart health.

Why Heart Health Matters

Obesity inextricably increases the risk of heart disease, stroke, and diabetes. Fortunately, many modern weight-loss medicines contribute directly to improved overall heart health and not *just* weight loss.

Two of the most effective weight management treatments available today at iQ Doctor are Wegovy (semaglutide) and Mounjaro (tirzepatide).

The Latest Research Into Weight Management Medication

A new real-world study of more than 21,000 patients was presented at the European Society of Cardiology (ESC) Congress in Madrid and reported by Reuters (Aug 31, 2024).

Patient Profile

• Patients who were overweight or obese
• Had cardiovascular disease (CVD)
• Did not have diabetes

Finding of the Study

• Wegovy was found to have contributed to a reduced risk of heart attack, stroke, or death by 57% when compared with Mounjaro
• Major heart events occurred in 15 people using Wegovy, whereas it major events occurred in 39 people who took Mounjaro
• Wegovy showed about a 29% lower CVD risk compared with tirzepatide

Unpacking the Findings: Why Wegovy May Contribute to Heart Health

Wegovy works by mimicking GLP-1, a naturally occurring hormone that:

• Reduces inflammation in blood vessels
• Improves overall blood flow
• Helps stabilise fatty deposits (plaques) in the arteries
• Lowers the chance of clot formation in the blood

Taking Wegovy can provide beneficial cardiovascular effects and can protect against heart attacks and strokes - even before major weight loss is required or occurs!

What about Mounjaro (and Other Weight Management Systems)?

Mounjaro works on utilising two naturally occurring hormones, those being GLP-1 and GIP. Whilst this makes Mounjaro very effective for weight loss and diabetes control, its exact effects on the heart are still under study.

Important Things to Know Regarding the Study

• This study was a real-world comparison of Wegovy and Mounjaro, not a controlled clinical trial
• Follow-up time was short (around 4 months), so more research is needed to confirm the long-term benefits of using Wegovy or Mounjaro for heart health
• Wegovy and Mounjaro medications do undoubtedly remain excellent choices for weight loss and management
• Wegovy helps people lose weight and has proven attributable heart benefits
• Mounjaro helps with weight loss (sometimes more), but heart health benefits are not yet clear
• If you have heart disease as well as obesity, iQ Doctor leans on the side of the empirical research which suggests Wegovy to be the better (current) option

Insights from the SELECT trial

The SELECT trial aimed to determine whether semaglutide (2.4mg weekly) could reduce the risk of major adverse cardiovascular events such as heart attack, stroke or cardiovascular death in people who were overweight or obese, and already living with cardiovascular disease - but without diabetes.

The SELECT trial showed that Wegovy (semaglutide 2.4 mg) cuts the risk of heart attack, stroke, or cardiovascular death by 20% in people with obesity and heart disease - but no diabetes.

Benefits appeared within months, even before major weight loss occurred. Weight loss of around 10% was sustained for up to 4 years, even without lifestyle changes.

Wegovy also reduced heart failure hospitalisations. Wegovy is now proven to support both weight loss and heart health - a major shift in obesity treatment. If you wish to discuss a medicated weight management plan, please feel free to book in a call with an expert iQ Doctor physician.

iQ Doctor is a registered UK pharmacy that specialises in medical remedies for weight loss, erectile dysfunction, hair loss support and much more. Whether you require over-the-counter relief, or prescription-only medication, the experts at iQ Doctor can assist. Please get in touch if you need any further advice.

Also, be sure to keep in touch with iQ Doctor via our social media channels as well as keeping up to date with us by signing up to the mailing list.

References

• Reuters. Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug. August 31, 2025
• American College of Cardiology (ACC). Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT). 2023